Key Developments in the Management of Melanoma: Current Combinations, Therapies in Development, and Sequencing Considerations
June 30, 2023
June 30, 2024
This activity is provided by Med Learning Group.
This activity is co-provided by AMEDCO
Nursing learners, view this Learner Notification prior to starting this activity
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the targeted educational needs of oncologists, nurse practitioners, oncology pharmacists, and physician assistants to ensure confidence in the management of advanced melanoma.
This educational enduring program will help healthcare professionals to optimize patient outcomes for those with advanced melanoma without actionable melanoma mutations. Specifically, the programming will improve clinicians’ knowledge of the latest data concerning appropriate assessment of melanoma from a clinical pathologic view and familiarize them with current updates with single-agent and combination therapy in advanced melanoma across settings of care, while preparing them to best manage adverse events across these therapies.
Upon completion of this activity, attendees should be able to:
- Cite the latest data concerning appropriate assessment of melanoma from a clinical pathologic view
- Summarize current updates with single-agent and combination therapy in melanomas across settings of care
- Assess the latest considerations in adverse event management across single-agent and combination therapies for melanoma
Adil Daud, MD
Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF
Director, Melanoma Clinical Research
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Allison Betof Warner, MD, PHD
Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
Physician Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Education Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure of Relevant Financial Relationship(s)
- Adil Daud, MD
- Consultant: Genoptix, GlaxoSmithKline, Oncosec, Caris, Eisai, and GLG
- Research: Bristol Myers Squibb, Checkmate Pharmaceuticals, Genentech/Roche (Inst), GlaxoSmithKline (Inst), Incyte, and Merck/Schering Ploug
- Allison Betof Warner, MD, PHD
- Consultant: Iovance Biotherapeutics, Novartis, Bluepath Solutions, Pfizer, Instil Bio, Lyell Immunopharma, Bristol Myers Squibb, and Immatics
- Research: Iovance
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed. The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer. The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group has nothing to disclose.
Vaidehee Deshpande, Ph.D., Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
Rashado Coote, Program Coordinator for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
Method of Participation
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the online post-test and evaluation
You will receive your certificate as a downloadable file.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: https://www.medlearninggroup.com/privacy-policy/
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org
Content - Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.